William Guyer News Today

StockNews.com upgraded shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a buy rating to a strong-buy rating in a research note published on Saturday morning. Several other equities research analysts have also commented on the stock. Truist Financial lifted their price target on shares of Corcept Therapeutics from $36.00 to $42.00 and gave the […]

C M Bidwell & Associates Ltd. bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,606 shares of the biotechnology company’s stock, valued at approximately $125,000. Other hedge […]

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.25 by $0.03, Briefing.com reports. The company had revenue of $135.41 million for the quarter, compared to analyst estimates of $129.27 million. Corcept Therapeutics had a net […]

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.25 by $0.03, Briefing.com reports. The company had revenue of $135.41 million for the quarter, compared to analyst estimates of $129.27 million. Corcept Therapeutics had a net […]

Burney Co. boosted its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 40.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 401,263 shares of the biotechnology company’s stock after purchasing an additional 115,006 shares during the quarter. Burney Co. owned […]

Hussman Strategic Advisors Inc. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 32.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 63,000 shares of the biotechnology company’s stock after selling 30,600 shares during the period. Hussman Strategic […]

Operator: Good day. And welcome to the Corcept Therapeutics Conference Call. [Operator Instructions] Please be advised that todays conference is being recorded.

Our readers share their opinions on a variety of topics